Artrya Ltd (ASX:AYA)’s John Barrington discusses the company’s first US partnership deal with Proactive’s Andrew Scott, detailing a clinical agreement with Huntsville Heart Center – a well-known cardiology centre – to assess the efficacy of the Artrya Salix Coronary Anatomy solution in detecting heart disease.
Artrya believes this partnership will offer the first opportunity to generate US-based revenue, and to deliver on the company’s core purpose of saving lives by assisting clinicians in rapidly detecting the causes of heart disease; the number one leading cause of death globally.